RMD / Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust more_horizontal

ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Invest more_horizontal

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth consid more_horizontal

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide. more_horizontal

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business. more_horizontal

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the st more_horizontal

ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from i more_horizontal

Some investors in ResMed, which makes machines for people with sleep apnea, think that effective new weight-loss drugs could shrink its addressable ma more_horizontal